NCT06678282View on ClinicalTrials.gov

JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia

NARecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 7, 2023

Primary Completion Date

September 30, 2026

Study Completion Date

December 31, 2026

Conditions
B-NHLB-ALL
Interventions
DRUG

JY231 Injection

The starting dose of this study was set at 1\~10×10\^6 transduction units (TU) / kg and escalated at 2\~5×107\^TU/kg and 6\~10×10\^7 TU/kg.

Trial Locations (1)

450000

RECRUITING

The First Affiliated Hospital of Zhengzhou University, Zhenzhou

All Listed Sponsors
lead

Shenzhen Genocury Biotech Co., Ltd.

INDUSTRY